Last reviewed · How we verify
Active Comparator Control 1
Active Comparator Control 1 is a pharmacologically inactive substance used as a control in clinical trials.
At a glance
| Generic name | Active Comparator Control 1 |
|---|---|
| Also known as | HLIM Placebo+SA160021+SA160022 Placebo |
| Sponsor | SamA Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
It does not have any therapeutic effect and is used to compare the efficacy of the active treatment. The exact mechanism of action is not applicable as it is a control substance.
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- The Effects of Commercially Available High Protein Drink on Amino Acid Bioavailability and Recovery From Muscle Fatiguing Exercise in 18-45-year-old Male and Female Participants. (NA)
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- KD Treatment for Super-refractory Status Epilepticus (NA)
- Examining the Effectiveness of Exercise Training After Cervical Laminoplasty Surgery (NA)
- Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia (NA)
- Phase I PK and Safety Study of Ondansetron Inhalation Powder (PHASE1)
- Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active Comparator Control 1 CI brief — competitive landscape report
- Active Comparator Control 1 updates RSS · CI watch RSS
- SamA Pharmaceutical Co., Ltd portfolio CI